–
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval from the US Food and Drug Administration (FDA) to market the generic equivalent to Evista (Raloxifene) Tablets, 60 mg, in the United States.
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva will begin shipping the product within the next 30 days.
Evista 60 mg Tablets marketed by Eli Lilly and Company, had annual sales of approximately $824 million in the United States, according to IMS data as of December 2013.
–
